Semaglutide: difference between revisions
Diff·revision 17 → 18·15:25, 21 Jan 2025
Difference between revision 17 and revision 18 of Semaglutide. 2 lines changed; the page grew by 365 bytes.
| Revision 17 — 22:02, 3 Jan 2025 NewLabNell (talk) expand §Pharmacokinetics 6,733 bytes +75 | Revision 18 — 15:25, 21 Jan 2025 ComparisonCato (talk) add the structural figure and caption it properly 7,098 bytes +365 | ||
|---|---|---|---|
| 52 | The [[STEP trial programme|STEP]] programme established the obesity indication and the [[SUSTAIN trial programme|SUSTAIN]] programme the glycaemic one; [[SELECT trial|SELECT]] and [[FLOW trial|FLOW]] added the outcome indications.{{r|wilding2021,lincoff2023}} | 52 | The [[STEP trial programme|STEP]] programme established the obesity indication and the [[SUSTAIN trial programme|SUSTAIN]] programme the glycaemic one; [[SELECT trial|SELECT]] and [[FLOW trial|FLOW]] added the outcome indications.{{r|wilding2021,lincoff2023}} |
| 53 | 53 | ||
| + | 54 | Results are means from trials that included intensive behavioural support and a structured escalation schedule. Individual response is widely distributed: in STEP 1 roughly a third of participants on active treatment lost 20% or more of body weight, and roughly one in seven lost less than 5%. The determinants of that spread are not established.{{r|wilding2021}} | |
| + | 55 | ||
| 54 | == References == | 56 | == References == |
| 55 | {{reflist}} | 57 | {{reflist}} |